Pfizer (PFE) Accounts Payables (2009 - 2026)

Pfizer (PFE) has reported Accounts Payables for 18 consecutive years, with $4.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables fell 11.32% year-over-year to $4.6 billion in Q2 2026; TTM through Jun 2026 was $4.6 billion, a 11.32% decrease from a year earlier, with the FY2025 full-year figure at $5.2 billion, down 6.98% from the prior year.
• Accounts Payables was $4.6 billion for Q2 2026 at Pfizer, up from $4.5 billion in the prior quarter.
• Over five years, Accounts Payables peaked at $6.8 billion in Q4 2022 and troughed at $4.5 billion in Q1 2026.
• A 5-year average of $5.6 billion and a median of $5.4 billion in 2022 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 43.47% in 2022 and dropped 16.05% in 2024, its largest moves.
• Over 5 years, Accounts Payables stood at $6.8 billion in 2022, then decreased by 1.45% to $6.7 billion in 2023, then retreated by 16.05% to $5.6 billion in 2024, then decreased by 6.98% to $5.2 billion in 2025, then declined by 12.58% to $4.6 billion in 2026.
• The last three Accounts Payables figures came in at $4.6 billion (Q2 2026), $4.5 billion (Q1 2026), and $5.2 billion (Q4 2025), per Business Quant data.